GYRE THERAPEUTICS, INC. (GYRE)
$6.59-$0.09 (-1.35%) Today
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 8 | 69,694 | $433K |
| Grant or award | 10 | 490,000 | |
| Option exercise | 16 | 139,388 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
45 Form 4 filings on record, the earliest from Dec 19, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Claire Weston - Director | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Maxwell Kirkby - Director | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Gordon Carmichael | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| David M. Epstein | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Dan Weng | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Renate Parry | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Ping Zhang | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Rodney L. Nussbaum | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 3,000 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 3,000 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 3,000 | $0.75 | $2K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 3,000 | $6.15 | $18K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 5,000 | $0.75 | $4K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 3,000 | $0.75 | $2K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 3,000 | $6.35 | $19K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 5,000 | $6.24 | $31K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 2,800 | $0.75 | $2K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 2,800 | $6.17 | $17K | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 2,800 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 14,500 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 6,418 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 14,500 | $0.75 | $11K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 6,418 | $0.75 | $5K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 14,500 | $6.14 | $89K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 6,418 | $6.21 | $40K | |
| Joshua Benjamin Bergmann - Officer | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
 Ying Luo - Officer | Grant or award | Stock Option (Right to Buy) | 120,000 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 19,575 | $0.75 | $15K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 15,401 | $0.75 | $12K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 19,575 | $6.13 | $120K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 15,401 | $6.40 | $99K | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 19,575 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 15,401 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 3,500 | $0.75 | $3K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 4,000 | $0.75 | $3K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 4,000 | $6.10 | $24K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 3,500 | $6.08 | $21K | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 3,500 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 4,000 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 9,400 | $0.75 | $7K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 12,820 | $0.75 | $10K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 9,400 | $6.15 | $58K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 12,820 | $6.15 | $79K | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 9,400 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 12,820 | $0.00 | - | |
| Ping Zhang | Derivative | Stock Option (Right to Buy) | 250,000 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 200 | $0.75 | $150 | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 9,120 | $0.75 | $7K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 200 | $6.62 | $1K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 9,120 | $6.37 | $58K | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 200 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 9,120 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 15,580 | $0.75 | $12K | |
| Weiguo Ye - Officer | Option exercise | Common Stock | 13,100 | $0.75 | $10K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 15,580 | $6.91 | $108K | |
| Weiguo Ye - Officer | Open-market sale | Common Stock | 13,100 | $6.65 | $87K | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 15,580 | $0.00 | - | |
| Weiguo Ye - Officer | Option exercise | Stock Option (Right to Buy) | 13,100 | $0.00 | - | |
| Ying Luo - Officer | Open-market sale | Common Stock | 179 | $8.01 | $1K | |
| Ying Luo - Officer | Open-market sale | Common Stock | 10,136 | $8.04 | $81K | |
| GNI Group Ltd. | Other | Series B Preferred Stock | 458,120 | - | - | |
| GNI Group Ltd. | Other | Series B Preferred Stock | 2,143,706 | - | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 95,060 | $0.00 | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 95,060 | $0.00 | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 47,530 | $0.00 | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 11,882 | $0.00 | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 33,271 | $0.00 | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 33,271 | $0.00 | - | |
| Thomas Wilson Eastling - Officer | Grant or award | Stock Option (Right to Buy) | 92,683 | $0.00 | - | |
| Ping Zhang | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Ruoyu Chen - Officer | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Dan Weng | Grant or award | Stock Option (Right to Buy) | 52,000 | $0.00 | - | |
| Ping Zhang | Grant or award | Stock Option (Right to Buy) | 250,000 | $0.00 | - | |
| Thomas Wilson Eastling | Grant or award | Stock Option (Right to Buy) | 26,000 | $0.00 | - | |
| Gordon Carmichael | Grant or award | Stock Option (Right to Buy) | 26,000 | $0.00 | - | |
| Renate Parry | Grant or award | Stock Option (Right to Buy) | 26,000 | $0.00 | - | |
| Rodney L. Nussbaum | Grant or award | Stock Option (Right to Buy) | 26,000 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
GYRE THERAPEUTICS, INC. (GYRE) had 14 insider filings in the last 90 days, with the most recent on 2026-08-05. The full record for GYRE runs to 45 Form 4 filings, the earliest from 2024-12-19. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of GYRE were filed in the last 90 days.
8 insider sales of GYRE were filed in the last 90 days, totaling $433K.
This page tracks GYRE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add GYRE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
